InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...
Taiwan News10h
Almadex Commences Drilling on the Sinter Zone, Paradise-Davis Project, Nevada
About the Sinter Zone, Paradise-Davis Project The sinter zone is located adjacent and to the north of the porphyry lithocap area (see map attached and Almadex news release of September 22, 2022) and ...
manilatimes15h
ArriVent BioPharma Reports Third Quarter 2024 Financial Results
Dr. Yao continued, "We expect several near-term catalysts for our firmonertinib program including initiating dose expansion for the combination study in classical EGFR mutant NSCLC with SHP2 inhibitor ...
cryptonews17h
The DFINITY Foundation Launches Three ‘Transformative Upgrades’
Read more about Cryptonews The DFINITY Foundation, a major contributor to the Internet Computer (ICP), has launched three ...